Nuclear Export Inhibitor Drugs Market

Nuclear Export Inhibitor Drugs Market:Global Industry Analysis 2015 - 2019 and Opportunity Assessment 2020 - 2030

Market Overview

Nuclear export inhibitor drugs bind with karyopherin, a protein that performs transport of other proteins and restricts uncontrolled transport of proteins which leads to spread of cancer cells. This tends to build up tumour suppressors in the nucleus of cancerous cells.  

Nuclear export inhibitor drugs market consists of anti-tumour drugs. According to WHO, globally cancer is the second leading cause of death with 1 out of every 6 deaths occurs due to cancer.

Hence, nuclear export inhibitor drugs market is expected to have significant growth during the forecast period to treat cancer. In June 2020, the U.S based pharmaceutical company Kyropharm received approval from U.S. FDA for the XPOVIO (Selinexor), a nuclear export inhibitor drugs for treatment of RR multiple myeloma (RRMM) and RR diffuse large b-cell lymphoma (RR DLBCL).

Covid-19 has led to a shift of focus for many biopharmaceuticals to find coronavirus cure delaying research process in nuclear export inhibitor drugs market. Manufacturing activities have been put on halt across various unit due to shut down.

Pandemic has led to the reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities.

Nuclear Export Inhibitor Drugs Market: Drivers and Restraints

The rise in prevalence of cancer across the globe acts as a major driving factor for nuclear export inhibitor drugs market growth. Increasing collaborative research and development activities among leading biopharmaceutical innovative players is expected to fuel growth of global nuclear export inhibitor drugs market.

In addition, clinical-stage development companies are allocating significant funds towards the development of nuclear export inhibitor drugs. For instance, in July 2020, Antengene Corporation, a leading oncology-focused biopharmaceutical company has raised US$97 million in series C funding to develop oral nuclear export inhibitor drugs.

Approval and commercialization of new therapeutics is expected to propel the growth of nuclear export inhibitor drugs market.  Rise in diagnostics and the treatment-seeking rate is expected to drive nuclear export inhibitor drugs market growth.

However, the side effects of the drugs challenge nuclear export inhibitor drugs market growth. Stringent drug regulatory requirements hinder the growth of the nuclear export inhibitor drugs market.

Nuclear Export Inhibitor Drugs Market: Overview

Selinexor is the most common drug holding a major share of the nuclear export inhibitor drugs market. Based on indication, breast cancer leads to huge revenue generation followed by pancreatic cancer in nuclear export inhibitor drugs market. Whereas, among the route of administration oral drugs hold a major revenue share of nuclear export inhibitor drugs market.

Hospital pharmacies is a leading distribution channel, due to the presence of patients based in hospitals followed by retail pharmacies. Online pharmacies are expected to have significant growth rate due to increased adoption of e-commerce activities in nuclear export inhibitor drugs market.

Nuclear Export Inhibitor Drugs Market: Region-wise Outlook

North America is expected to continue dominating the nuclear export inhibitor drugs market during the forecast period with an increasing prevalence of cancer in the region. Ease of reimbursement will lead to growth of nuclear export inhibitor drugs market in North America in the coming decade.

Europe holds significant revenue share in nuclear export inhibitor drugs market with rise rate of approval and commercialization in the region. Asia-Pacific nuclear export inhibitor drugs market is expected to have higher growth rate during the forecast period owing to increased product penetration and large patient population in the.

Improving health infrastructure creates Asia-Pacific nuclear export inhibitor drugs market to grow during the forecast period. Middle East and Africa will observe least growth in nuclear export inhibitor drugs market due to poor healthcare infrastructure and economic conditions.

Nuclear Export Inhibitor Drugs Market: Key Market Participants

Major players in nuclear export inhibitor drugs market include

  • Pfizer Inc. 
  • Johnson & Johnson Inc.
  • Bayer AG 
  • AstraZeneca 
  • Teva Pharmaceuticals Industries Ltd. 
  • GlaxoSmithKline Plc.
  • Karyopharm Therapeutics Inc. 
  • Millennium Pharmaceuticals Inc.
  •  Antengene Corporation

The research report on nuclear export inhibitor drugs market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.

The research report on nuclear export inhibitor drugs market provides analysis and information according to market segments such as drug class, route of administration, application, and region.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Europe (Germany, Italy, France, U.K, Spain, Russia)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, ASEAN)
  • Oceania (Australia, New Zealand)
  • Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

Nuclear Export Inhibitor Drugs Market Segmentation

drug type

  • Selinexor 
  • Leptomycin B
  • Aminoratjadone

indication

  • Pancreatic cancer
  • Breast cancer
  • Lung cancer
  • Melanoma
  • Acute and chronic leukaemia
  • Lymphoma
  • Others 

route of administration

  • Oral 
  • Intravenous 

distribution channel

  • Hospital Pharmacies 
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports

Recommendations

Nuclear Export Inhibitor Drugs Market